[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465926":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":56,"collaborators":22,"id":60,"slug":22,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":22,"enrollmentInfo":68,"targetDuration":22,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":42,"whyStopped":22,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Kyoto University, Graduate School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin","ACTIVE_COMPARATOR","Aspirin 100 mg\u002Fday",[13],"Drug: Aspirin",{"label":15,"type":10,"description":15,"interventionNames":16},"No Aspirin",[17],"Drug: No aspirin",[19,23],{"type":20,"name":9,"description":11,"armGroupLabels":21,"otherNames":22},"DRUG",[9],null,{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"No aspirin","No aspirin administered",[15],[28],{"name":29,"affiliation":5,"role":30},"Takeshi Kimura, MD, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":22,"email":35},"CONTACT","+81-75-751-4255","taketaka@kuhp.kyoto-u.ac.jp",{"name":37,"role":33,"phone":34,"phoneExt":22,"email":38},"Erika Yamamoto, MD, PhD","erkymmt@kuhp.kyoto-u.ac.jp",[40],{"facility":41,"status":42,"city":43,"state":22,"zip":22,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Kyoto University Hospital","RECRUITING","Kyoto","Japan","JP",{"type":47,"coordinates":48},"Point",[49,50],135.75385,35.02107,{"lat":50,"lon":49},[53,54,55],{"name":29,"role":33,"phone":34,"phoneExt":22,"email":22},{"name":37,"role":33,"phone":34,"phoneExt":22,"email":38},{"name":29,"role":30,"phone":22,"phoneExt":22,"email":22},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Takeshi Morimoto","Study Statistician","100465926",false,"NCT05347069","Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization","ASA-IN","Inclusion Criteria:\n\n* Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels\u002Fmajor branches on coronary CT or coronary angiography but not eligible for coronary revascularization\n* Patients for whom consent can be obtained\n\nExclusion Criteria:\n\n* Patients with history of acute coronary syndromes (ACS)\n* Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\n* Patients with left main trunk stenosis (≥50%)\n* Patients for whom aspirin administration is mandatory\n* Patients undergoing antithrombotic therapy other than aspirin\n* Patients with atrial fibrillation\n* Patients with history of stroke within six months\n* Patients scheduled for major surgical procedures that will require aspirin discontinuation\n* Patients with contraindication of aspirin\n* Patients expected to have a prognosis of 1 year or less due to comorbidities\n* Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization\n* Patients who are judged by attending physicians to be inappropriate to participate in this study","ALL","20 Years",{"count":69,"type":70},2890,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.",[76,77,78],"Stable Angina Pectoris","Coronary Artery Disease","Ischemic Heart Disease",[80,9],"Chronic Coronary Syndrome","2025-03-08",{"date":83,"type":84},"2025-03-11","ACTUAL",{"date":86,"type":84},"2022-06-14",{"date":88,"type":70},"2030-12",{"name":58,"class":6},1]